274903-84-3

Basic information

• Product Name: 3-[4-[4-[4-[(E)-2-Carboxyvinyl]phenyl]-5-[4-[(E)-3-(hexadecylamino)-3-oxo-1-propenyl]phenyl]-1H-imidazol-2-yl]phenyl]-4,5-dihydroisoxazole-5-carboxylic acid
• Synonyms: OC-229-648
• CAS NO: 274903-84-3
• Molecular Formula: C₄₇H₅₆N₄O₆
• Molecular Weight: 772.99357
• Mol File: 274903-84-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-[4-[4-[4-[(E)-2-Carboxyvinyl]phenyl]-5-[4-[(E)-3-(hexadecylamino)-3-oxo-1-propenyl]phenyl]-1H-imidazol-2-yl]phenyl]-4,5-dihydroisoxazole-5-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[4-[4-[4-[(E)-2-Carboxyvinyl]phenyl]-5-[4-[(E)-3-(hexadecylamino)-3-oxo-1-propenyl]phenyl]-1H-imidazol-2-yl]phenyl]-4,5-dihydroisoxazole-5-carboxylic acid(274903-84-3)
• EPA Substance Registry System: 3-[4-[4-[4-[(E)-2-Carboxyvinyl]phenyl]-5-[4-[(E)-3-(hexadecylamino)-3-oxo-1-propenyl]phenyl]-1H-imidazol-2-yl]phenyl]-4,5-dihydroisoxazole-5-carboxylic acid(274903-84-3)

Safety Data

• Hazardous Substances Data: 274903-84-3(Hazardous Substances Data)

Upstream product

• 274904-27-7 (E)-3-(4-{2-[4-((E)-2-Hexadecylcarbamoyl-vinyl)-phenyl]-2-oxo-acetyl}-phenyl)-acrylic acid tert-butyl ester 
• 21216-80-8 N-cetylacrylamide 
• 274903-83-2 3-(4-{4-[4-((E)-2-tert-butoxycarbonyl-vinyl)phenyl]-5-[4-(2-hexadecylcarbamoyl-vinyl)phenyl]-1H-imidazol-2-yl}phenyl)-4,5-dihydroisoxazole-5-carboxylic acid tert-butyl ester 
• 35578-47-3 4,4'-dibromobenzil 
• 143-27-1 hexadecylamine 

Relevant articles and documents

Development of potent non-carbohydrate imidazole-based small molecule selectin inhibitors with antiinflammatory activity

A novel series of non-carbohydrate imidazole-based selectin inhibitors has been discovered via high-throughput screening using a P-selectin ELISA-based assay system. The initial lead 1 had an IC50 of 17 μM in the P-selectin ELISA; this potency was significantly improved via an extensive SAR exploration. One of the current lead compounds (29) has an IC50 of 300 nM in a P-selectin ELISA; it also has good activity in P- and E-selectin cell adhesion assays and shows efficacy in vivo. These compounds represent a novel series of sLeX mimetics with antiinflammatory activity. Their unique profile supports our interest in their further evaluation as drug candidates for the treatment of inflammation. Herein we describe the syntheses, optimization, and SAR of this series of novel potent selectin antagonists.